Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Email: sales @ radiantinsights. com Web: http:// www. radiantinsights. com /
Request A Sample Copy Of This Report at: http:// www. radiantinsights. com / research / frontier-pharma-type-2-diabetes-mellitus-gpcrsand-protein-kinases-dominate-pipeline / request-sample
Reason to Buy:
This report will allow you to-
‣ Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, and treatment options. Identify leading products and companies within the market, as well as key unmet needs, in order to gain a competitive understanding of gaps in the current market.
‣ Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
‣ Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, all firstin-class targets in the T2DM pipeline have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
‣ Consider first-in-class pipeline products with no prior involvement in licensing and codevelopment deals that may represent potential investment opportunities.
Scope:
The escalating T2DM public healthcare need has resulted in a competitive market landscape
‣ What is the pathophysiology of T2DM?
‣ What are the common co-morbidities and complications?
‣ How has the emergence of new drug classes in the past decade impacted the treatment algorithm?
‣ What are the most significant unmet needs within the market?
The T2DM pipeline is large and innovative
‣ Which molecule types and molecular targets are most prominent within the pipeline?
‣ Which first-in-class targets are most promising?
‣ How does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?
The T2DM deals landscape is highly active
‣ Do T2DM products attract high deal values?
‣ Which molecule types and molecular targets dominate the deals landscape?
‣ Which first-in-class pipeline products have no prior involvement in licensing or codevelopment deals?
https
:// www. facebook. com / RadiantInsights
https:// www. linkedin. com / company / radiant-insights https:// twitter. com / radiantinsights
https:// plus. google. com /+ Radiantinsights